Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Hexaell to Start China Trial of Novel Drug-Device for Chronic Liver Failure

publication date: Dec 6, 2022

Shanghai Hexaell Biotech was cleared to start China clinical trials of HepaCure, a novel device-drug combination aimed at restoring liver function in patients with acute-on-chronic liver failure. The bioartificial liver support system is a promising alternative for partial liver functions such as metabolic detoxification and protein synthesis. HepaCure’s hiHeps cell therapy is a cell transdifferentiation technology that directly converts human fibroblasts derived from umbilical cords to hepatocyte like cells with liver cell functions. The drug-device has shown positive results in investigator-led studies. More details....



Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital